Oklo reports progress toward first criticality at Groves Isotopes Test Reactor and enters agreements to provide nuclear power for AI data centers operated by Meta Platforms and Switch.

Oklo achieved key regulatory approvals and is advancing toward first criticality at its Groves Isotopes Test Reactor. The company has also joined the U.S. Department of Energy's Surplus Plutonium Utilization Program in partnership with newcleo to pursue advanced fuel sourcing.

Oklo entered agreements to supply advanced nuclear power to AI-focused data centers operated by Meta Platforms and Switch. The company also acquired Atomic Alchemy to expand into medical and industrial radioisotopes markets.

Oklo trades at $58.09, down 27.0% over the past month and down 25.3% year to date, though up 15.5% over the past year. The company reports less than US$1m in revenue and remains loss-making.